PPARA and metabolic dysfunction-associated steatohepatitis: Taking into account that due to species differences the response to some targets, like PPAR-α, may be overrepresented in animal models, we infer that elafibranor will be particularly useful to reduce hepatic inflammation and could be a pharmacologically useful agent, probably in combination with other agents, for human NASH.